Skip to main content

BIOLOGIA DE SISTEMAS DE RIBORREGULACION SINTETICA: TERMODINAMICA, RUIDO Y OPERABILIDAD

PRE2019-088531

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Multiplexable and Biocomputational Virus Detection by CRISPR-Cas9-Mediated Strand Displacement

  • Márquez-Costa, Rosa
  • Montagud-Martínez, Roser
  • Marques, Maria Carmen
  • Albert, Eliseo
  • Navarro, David
  • Ruiz, Raúl
  • Rodrigo Tarrega, Guillermo
  • Daròs, José-Antonio|||0000-0002-6535-2889
[EN] Recurrent disease outbreaks caused by different viruses, including the novel respiratory virus SARS-CoV-2, are challenging our society at a global scale; so versatile virus detection methods would enable a calculated and faster response. Here, we present a novel nucleic acid detection strategy based on CRISPR-Cas9, whose mode of action relies on strand displacement rather than on collateral catalysis, using the Streptococcus pyogenes Cas9 nuclease. Given a pre-amplification process, a suitable molecular beacon interacts with the ternary CRISPR complex upon targeting to produce a fluorescent signal. We show that SARS-CoV-2 DNA amplicons generated from patient samples can be detected with CRISPR-Cas9. We also show that CRISPR-Cas9 allows the simultaneous detection of different DNA amplicons with the same nuclease, either to detect different SARS-CoV-2 regions or different respiratory viruses. Furthermore, we demonstrate that engineered DNA logic circuits can process different SARS-CoV-2 signals detected by the CRISPR complexes. Collectively, this CRISPR-Cas9 R-loop usage for molecular beacon opening (COLUMBO) platform allows a multiplexed detection in a single tube, complements the existing CRISPR-based methods, and displays diagnostic and biocomputing potential., This work was supported by the Fondo Supera Covid-19 from CRUE and Banco Santander (Grant COV-CRISPIS to G.R.), the CSIC PTI Salud Global (Grant SGL2021-03-040 to G.R.) through the NextGenerationEU Fund (regulation 2020/2094), the Spanish Ministry of Science and Innovation (Grants PGC2018-101410-B-I00 to G.R. and PID2020-114691RB-I00 to J.A.D., both cofinanced by the European Regional Development Fund), and the Regional Government of Valencia (Grants SEJI/2020/011 and GVA-COVID19/2021/036 to G.R.). R.M.C. was supported by a predoctoral fellowship from the Spanish Ministry of Science and Innovation (PRE2019-088531). Publication fees covered by the CSIC Open Access Publication Support Program.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Diagnostics of Infections Produced by the Plant Viruses TMV, TEV, and PVX with CRISPR-Cas12 and CRISPR-Cas13

  • Marqués, María-Carmen
  • Sánchez-Vicente, Javier
  • Ruiz, Raúl
  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Gómez, Gustavo
  • Rodrigo Tarrega, Guillermo
  • CARBONELL, ALBERTO|||0000-0001-5628-6632
  • Daròs, José-Antonio|||0000-0002-6535-2889
[EN] Viral infections in plants threaten food security. Thus, simple and effective methods for virus detection are required to adopt early measures that can prevent virus spread. However, current methods based on the amplification of the viral genome by polymerase chain reaction (PCR) require laboratory conditions. Here, we exploited the CRISPR-Cas12a and CRISPR-Cas13a/d systems to detect three RNA viruses, namely, Tobacco mosaic virus, Tobacco etch virus, and Potato virus X, in Nicotiana benthamiana plants. We applied the CRISPR-Cas12a system to detect viral DNA amplicons generated by PCR or isothermal amplification, and we also performed a multiplexed detection in plants with mixed infections. In addition, we adapted the detection system to bypass the costly RNA purification step and to get a visible readout with lateral flow strips. Finally, we applied the CRISPR-Cas13a/d system to directly detect viral RNA, thereby avoiding the necessity of a preamplification step and obtaining a readout that scales with the viral load. These approaches allow for the performance of viral diagnostics within half an hour of leaf harvest and are hence potentially relevant for field-deployable applications., This work was supported by the Fondo Supera Covid-19 from CRUE and Banco Santander (grant COV-CRISPIS to G.R.) ; the Spanish Ministry of Science, Innovation, and Universities (grants PGC2018-101410-B-I00 to G.R. and PID2020-114691RB-I00 to J.-A.D., co-financed by the European Regional Development Fund) ; and the Regional Government of Valencia (grant SEJI/2020/011 to G.R.) . R.M.-C. was supported by a predoctoral fellowship from the Spanish Ministry of Science, Innovation, and Universities (PRE2019-088531) .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Engineering of CRISPR-Cas9-Based Systems for Diagnostics and Biocomputing

  • Márquez Costa, Rosa
[ES] Los sistemas CRISPR-Cas se basan en un mecanismo del sistema inmune adaptativo que se encuentra en bacterias y arqueas. Funcionan utilizando endonucleasas guiadas por ARN (proteínas Cas) para localizar y reconocer secuencias específicas de ácidos nucleicos. Los sistemas CRISPR-Cas son revolucionarios en el campo de la ingeniería genética, permitiendo la edición específica del genoma, ensayos de regulación genética y, desarrolladas en los últimos años, aplicaciones de diagnóstico. Los métodos de detección de ácidos nucleicos son la técnica de diagnóstico de referencia en la clínica debido a su alta sensibilidad y especificidad. Sin embargo, de cara al futuro, debemos desarrollar métodos versátiles de detección de virus que permitan diagnósticos rápidos y fiables, que superen las limitaciones de las técnicas actuales y puedan usarse fácilmente fuera del laboratorio para aplicaciones en puntos de atención (POC). Los sistemas CRISPR-Cas se han reconvertido en herramientas de diagnóstico de ácidos nucleicos gracias a la capacidad de algunas proteínas Cas de realizar cortes colaterales no específicos al reconocer su diana. Nuestro objetivo es ampliar el conjunto de herramientas de diagnóstico CRISPR-Cas mediante el desarrollo de una nueva estrategia de detección de ácidos nucleicos basada en CRISPR-Cas9, cuyo modo de acción se basa en el desplazamiento de hebra en lugar de en la catálisis colateral. Demostramos que los amplicones de ADN del SARS-CoV-2 generados a partir de muestras de pacientes pueden detectarse con CRISPR-Cas9. También demostramos la capacidad de realizar la detección simultánea de diferentes amplicones de ADN con la misma nucleasa, ya sea para identificar diferentes regiones de SARS-CoV-2 o diferentes virus respiratorios. Para avanzar hacia aplicaciones POC, acoplamos el paso de preamplificación isotérmica con oligos biotinilados para producir amplicones marcados. Cuando se combina con CRISPR-Cas9 y sondas marcadas con FAM, esto permite la visualización colorimétrica de la detección mediante ensayos de flujo lateral (LFA) en tiras disponibles en el mercado. La lectura colorimétrica permite la interpretación de los resultados a simple vista, superando la necesidad de un fluorímetro. Detectamos con éxito SARS-CoV-2 a partir de muestras de pacientes en la configuración LFA, y cuando se combinó con RT-RPA multiplexado, se logró la detección de dos regiones distintas del virus en una sola prueba. Además, la ausencia de actividad colateral en nuestra metodología permite el procesamiento de secuencias posteriores adicionales. Por lo tanto, también pretendemos explorar la capacidad de integración de señales de nuestro método de detección basado en CRISPR-Cas9. Demostramos que diseños de circuitos lógicos de ADN pueden procesar diferentes señales de SARS-CoV-2 detectadas por los complejos CRISPR. También nos propusimos mejorar nuestro sistema CRISPR-Cas9 para detectar tanto proteínas como ácidos nucleicos. Nos propusimos diseñar un ARN guía condicional que respondiera a la presencia de la proteína spike del SARS-CoV-2. Para ello, insertamos un aptámero en el ARN guía para bloquear la actividad de Cas9 en ausencia de la proteína. En presencia de la proteína spike, la interacción aptámero-proteína hace que el motivo de bloqueo sufra un cambio conformacional, liberando el ARN guía y activando Cas9. Aunque logramos con éxito el escenario de bloqueo utilizando las secuencias reguladoras, es necesario seguir trabajando para identificar una secuencia que pueda inducir el cambio conformacional específico necesario para restaurar la actividad de Cas9 en presencia de la proteína spike. En conjunto, esta plataforma de diagnóstico CRISPR-Cas9 permite una detección multiplexada en un solo tubo, complementando los métodos existentes basados en CRISPR, y ofreciendo un sistema extensible para aplicaciones en diagnóstico en el punto de atención y biocomputación., [CA] Els sistemes CRISPR-Cas es basen en un mecanisme del sistema immunitari adaptatiu que es troba en bacteris i arqueus. Funcionen utilitzant endonucleases guiades per ARN (proteïnes Cas) per tal de dirigir-se i reconéixer seqüències específiques d'àcids nucleics. Els sistemes CRISPR-Cas siguen revolucionaris en el camp de l'enginyeria genètica, permetent l'edició específica del genoma, assajos de regulació gènica i, desenvolupades en els darrers anys, aplicacions de diagnòstic. Els mètodes de detecció d'àcids nucleics són la tècnica de diagnòstic de referència a la clínica degut a la seua alta sensibilitat i especificitat. No obstant, de cara al futur, hem de desenvolupar mètodes versàtils de detecció de virus que permeten diagnòstics ràpids i fiables, que superen les limitacions de les tècniques actuals i puguen utilitzar-se fàcilment fora del laboratori per a aplicacions en punts d'atenció (POC). Els sistemes CRISPR-Cas han estat reorientats com a eines de diagnòstic d'àcids nucleics, fet possible per la capacitat d'algunes proteïnes Cas de realitzar un tall col·lateral no específic en reconèixer un objectiu. El nostre objectiu és ampliar el conjunt d'eines de diagnòstic CRISPR-Cas desenvolupant una nova estratègia de detecció d'àcids nucleics basada en CRISPR-Cas9, el mode d'acció del qual es basa en el desplaçament de cadena en lloc de la catàlisi col·lateral. Mostrem que es poden detectar amplicons de DNA de SARS-CoV-2 generats a partir de mostres de pacients amb CRISPR-Cas9. També demostrem la capacitat de realitzar la detecció simultània de diferents amplicons de DNA amb la mateixa nucleasa, ja siga per identificar diferents regions de SARS-CoV-2 o diferents virus respiratoris. Per avançar cap a aplicacions de punt d'atenció (POC), vam combinar el pas de preamplificació isotèrmica amb oligos biotinilats per produir amplicons etiquetats. Quan es combinen amb l'orientació CRISPR-Cas9 i sondes etiquetades amb FAM, això permet la visualització colorimètrica de la detecció mitjançant assajos de flux lateral (LFA) en tires comercials disponibles. La lectura colorimètrica permet la interpretació dels resultats a simple vista, superant la necessitat d'un fluorímetre. Vam detectar amb èxit el SARS-CoV-2 a partir de mostres de pacients en el sistema LFA, i quan es va combinar amb RT-RPA multiplexada, es va aconseguir la detecció de dues regions diferents del virus en una sola prova. A més, l'absència d'activitat col·lateral en la nostra metodologia permet el processament de seqüències addicionals. Per tant, també ens proposem explorar la capacitat d'integració de senyals del nostre mètode de detecció basat en CRISPR-Cas9. Demostrem que els circuits lògics d'ADN dissenyats poden processar diferents senyals de SARS-CoV-2 detectats pels complexos CRISPR. També vam intentar millorar el nostre sistema CRISPR-Cas9 per detectar tant proteïnes com àcids nucleics. Ens vam proposar dissenyar un ARN guia condicional que respon a la presència de la proteïna spike del SARS-CoV-2. Per aconseguir-ho, vam inserir una seqüència d'aptàmer dins de l'ARN guia per bloquejar l'activitat de Cas9 en absència de la proteïna. En presència de la proteïna spike, la interacció aptàmer-proteïna fa que el motiu de bloqueig experimente un canvi conformacional, alliberant l'ARN guia i activant Cas9. Tot i que vam aconseguir amb èxit el bloqueig utilitzant les seqüències reguladores, es necessita més treball per identificar una seqüència que puga induir el canvi conformacional específic necessari per restaurar l'activitat de Cas9 en presència de la proteïna spike. Col·lectivament, aquesta plataforma de diagnòstic CRISPR-Cas9 permet una detecció multiplexada en un sol tub, complementant els mètodes existents basats en CRISPR i oferint un sistema extensible per a aplicacions en diagnòstics de punt d'atenció i biocomputació., [EN] CRISPR-Cas systems are based on an adaptive immune system mechanism found in bacteria and archaea. They function using RNA-guided endonucleases (Cas proteins), to target and recognize specific nucleic acid sequences. CRISPR-Cas systems are revolutionary in the field of genetic engineering, enabling specific genome editing, gene regulation assays and, developed in recent years, diagnostic applications. Nucleic acid detection methods are the gold-standard diagnostic technique in the clinic due to their high sensitivity and specificity. However, going forward, we must develop versatile virus detection methods that enable fast and reliable diagnostics and that can overcome the limitations of the current techniques and can be easily used outside the laboratory for point-of-care (POC) applications. CRISPR-Cas systems have been repurposed as nucleic acid diagnostic tools made possible by the ability of some Cas proteins to perform non-specific collateral cleavage upon target recognition. We aim to expand the CRISPR-Cas diagnostic toolkit by developing a novel nucleic acid detection strategy based on CRISPR-Cas9, whose mode of action relies on strand displacement rather than on collateral catalysis. We show that SARS-CoV-2 DNA amplicons generated from patient samples can be detected with CRISPR-Cas9. We also demonstrate the ability to perform simultaneous detection of different DNA amplicons with the same nuclease, either to identify different SARS-CoV-2 regions or different respiratory viruses. To advance toward POC applications, we coupled the isothermal preamplification step with biotinylated oligos to produce labelled amplicons. When combined with CRISPR-Cas9 targeting and FAM-labelled probes, this allows for colorimetric visualization of detection using lateral flow assays (LFA) on commercially available strips. The colorimetric readout enables interpretation of the results with the naked eye, surpassing the need for a fluorimeter. We successfully detected SARS-CoV-2 from patient samples in the LFA setup, and when combined with multiplexed RT-RPA, the detection of two distinct regions of the virus was achieved in a single test. Furthermore, the absence of collateral activity in our methodology allows for the processing of additional downstream sequences. Therefore, we also aim to explore the signal integration capability of our CRISPR-Cas9-based detection method. We demonstrate that engineered DNA logic circuits can process different SARS-CoV-2 signals detected by the CRISPR complexes. We also aimed to enhance our CRISPR-Cas9 system to sense both proteins and nucleic acids. We aimed to engineer a conditional guide RNA that responds to the presence of the SARS-CoV-2 spike protein. To achieve this, we inserted an aptamer sequence within the guide RNA to block Cas9 activity in the absence of the protein. Upon the presence of the spike protein, aptamer-protein interaction makes the blocking motif undergo a conformational change, releasing the guide RNA and activating Cas9. While we successfully achieved the blocking scenario using the regulatory sequences, further work is needed to identify a sequence that can induce the specific conformational change required to restore Cas9 activity upon spike protein presence. Collectively, this CRISPR-Cas9 diagnostic platform allows a multiplexed detection in a single tube, complementing the existing CRISPR-based methods, and offering an extensible system for applications in point-of-care diagnostics and biocomputing., This work was supported by a predoctoral fellowship from the Spanish Ministry of Science and Innovation (PRE2019-088531).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

CRISPR-Cas12a-Based Detection of SARS-CoV-2 Harboring the E484K Mutation

  • Marqués, María-Carmen
  • Ruiz, Raúl
  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Albert, Sandra
  • Domingo-Calap, Pilar
  • Rodrigo Tarrega, Guillermo
[EN] The novel respiratory virus SARS-CoV-2 is rapidly evolving across the world with the potential of increasing its transmission and the induced disease. Here, we applied the CRISPR-Cas12a system to detect, without the need of sequencing, SARS-CoV-2 genomes harboring the E484K mutation, first identified in the Beta variant and catalogued as an escape mutation. The E484K mutation creates a canonical protospacer adjacent motif for Cas12a recognition in the resulting DNA amplicon, which was exploited to obtain a differential readout. We analyzed a series of fecal samples from hospitalized patients in Valencia (Spain), finding one infection with SARS-CoV-2 harboring the E484K mutation, which was then confirmed by sequencing. Overall, these results suggest that CRISPR diagnostics can be a useful tool in epidemiology to monitor the spread of escape mutations., We thank M. Carmen Montaner, Javier Peman, Miguel Salavert, and Alba Ruiz from the Hospital Universitario y Politecnico La Fe for their support in the collection of the fecal samples. This work was supported by the Fondo Supera COVID-19 from CRUE and Banco Santander (Grant COV-CRISPIS, BOE-A-2020-7995, to GR), the CSIC PTI Salud Global (Grant SGL2021-03-040, to GR, and Grants 202020E292 and SGL2103034, to PDC) through the European Union-Next Generation EU, the Fondo COVID-19 from the Instituto de Salud Carlos III (Grant COV20/00210, to PDC), and the Generalitat Valenciana (Grant SEJI/2020/011, to GR). PDC was supported by the Ramon y Cajal program (RYC2019-028015-I) and RMC by a predoctoral fellowship (PRE2019-088531), both from the Spanish Ministerio de Ciencia e Innovacion.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diagnostics of infections produced by the plant viruses TMV, TEV, and PVX with CRISPR-Cas12 and CRISPR-Cas13

  • Marqués, M. Carmen
  • Sánchez-Vicente, Javier
  • Ruiz, Raúl
  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Gómez, Gustavo
  • Carbonell, Alberto
  • Daròs Arnau, José Antonio
  • Rodrigo, Guillermo
Viral infections in plants threaten food security. Thus, simple and effective methods for virus detection are required to adopt early measures that can prevent virus spread. However, current methods based on the amplification of the viral genome by polymerase chain reaction (PCR) require laboratory conditions. Here, we exploited the CRISPR-Cas12a and CRISPR-Cas13a/d systems to detect three RNA viruses, namely, Tobacco mosaic virus, Tobacco etch virus, and Potato virus X, in Nicotiana benthamiana plants. We applied the CRISPR-Cas12a system to detect viral DNA amplicons generated by PCR or isothermal amplification, and we also performed a multiplexed detection in plants with mixed infections. In addition, we adapted the detection system to bypass the costly RNA purification step and to get a visible readout with lateral flow strips. Finally, we applied the CRISPR-Cas13a/d system to directly detect viral RNA, thereby avoiding the necessity of a preamplification step and obtaining a readout that scales with the viral load. These approaches allow for the performance of viral diagnostics within half an hour of leaf harvest and are hence potentially relevant for field-deployable applications., This work was supported by the Fondo Supera Covid-19 from CRUE and Banco Santander (grant COV-CRISPIS to G.R.); the Spanish Ministry of Science, Innovation, and Universities (grants PGC2018-101410-B-I00 to G.R. and PID2020114691RB-I00 to J.-A.D., co-financed by the European Regional Development Fund); and the Regional Government of Valencia (grant SEJI/2020/011 to G.R.). R.M.-C. was supported by a predoctoral fellowship from the Spanish Ministry of Science, Innovation, and Universities (PRE2019088531), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Programmable regulation of translation by harnessing the CRISPR-Cas13 system

  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Rodrigo, Guillermo
The ability to control protein expression at both the transcriptional and post-transcriptional levels is instrumental for the cell to integrate multiple molecular signals and then reach high operational sophistication. Although challenging, fully artificial regulations at different levels are required for boosting systems and synthetic biology. Here, we report the development of a novel framework to regulate translation by repurposing the CRISPR-Cas13 immune system, which uses an RNA-guided ribonuclease. By exploiting a cell-free expression system for prototyping gene regulatory structures, our results demonstrate that CRISPR-dCas13a ribonucleoproteins (d means catalytically dead) can be programmed to repress or activate translation initiation. The performance assessment of the engineered systems also revealed guide RNA design principles. Moreover, we show that the system can work in vivo. This development complements the ability to regulate transcription with other CRISPR-Cas systems and offers potential applications., This work was supported by the grants PGC2018-101410-B-I00 from the Spanish Ministry of Science, Innovation, and Universities (co-financed by the European Regional Development Fund) and SEJI/2020/011 from the Regional Government of Valencia (to GR). RMC held a predoctoral fellowship (PRE2019-088531)., Publication fees covered by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multiplexable and biocomputational virus detection by CRISPR-Cas9-mediated strand displacement

  • Márquez-Costa, Rosa
  • Montagud-Martínez, Roser
  • Marqués, M. Carmen
  • Albert, Eliseo
  • Navarro, David
  • Daròs Arnau, José Antonio
  • Ruiz, Raúl
  • Rodrigo, Guillermo
Recurrent disease outbreaks caused by different viruses, including the novel respiratory virus SARS-CoV-2, are challenging our society at a global scale; so versatile virus detection methods would enable a calculated and faster response. Here, we present a novel nucleic acid detection strategy based on CRISPR-Cas9, whose mode of action relies on strand displacement rather than on collateral catalysis, using the Streptococcus pyogenes Cas9 nuclease. Given a preamplification process, a suitable molecular beacon interacts with the ternary CRISPR complex upon targeting to produce a fluorescent signal. We show that SARS-CoV-2 DNA amplicons generated from patient samples can be detected with CRISPR-Cas9. We also show that CRISPR-Cas9 allows the simultaneous detection of different DNA amplicons with the same nuclease, either to detect different SARS-CoV-2 regions or different respiratory viruses. Furthermore, we demonstrate that engineered DNA logic circuits can process different SARS-CoV-2 signals detected by the CRISPR complexes. Collectively, this CRISPR-Cas9 R-loop usage for the molecular beacon opening (COLUMBO) platform allows a multiplexed detection in a single tube, complements the existing CRISPR-based methods, and displays diagnostic and biocomputing potential., This work was supported by the Fondo Supera Covid-19 from CRUE and Banco Santander (Grant COV-CRISPIS to G.R.), the CSIC PTI Salud Global (Grant SGL2021-03-040 to G.R.) through the NextGenerationEU Fund (regulation 2020/2094), the Spanish Ministry of Science and Innovation (Grants PGC2018-101410-B-I00 to G.R. and PID2020-114691RB-I00 to J.A.D., both cofinanced by the European Regional Development Fund), and the Regional Government of Valencia (Grants SEJI/2020/011 and GVA-COVID19/2021/036 to G.R.). R.M.C. was supported by a predoctoral fellowship from the Spanish Ministry of Science and Innovation (PRE2019-088531)., Publication fees covered by the CSIC Open Access Publication Support Program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

On the ever-growing functional versatility of the CRISPR-Cas13 system

  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Heras-Hernández, María
  • Dolcemascolo, Roswitha
  • Rodrigo, Guillermo
CRISPR-Cas systems evolved in prokaryotes to implement a powerful antiviral immune response as a result of sequence-specific targeting by ribonucleoproteins. One of such systems consists of an RNA-guided RNA endonuclease, known as CRISPR-Cas13. In very recent years, this system is being repurposed in different ways in order to decipher and engineer gene expression programmes. Here, we discuss the functional versatility of the CRISPR-Cas13 system, which includes the ability for RNA silencing, RNA editing, RNA tracking, nucleic acid detection and translation regulation. This functional palette makes the CRISPR-Cas13 system a relevant tool in the broad field of systems and synthetic biology., Ministerio de Ciencia e Innovación,Grant/Award Number: PDC2022-133941- I00, PGC2018-101410- B- I00and PRE2019- 088531; EuropeanCommission, Grant/Award Number:813239; Consejo Superior deInvestigaciones Cientificas, Grant/AwardNumber: JAEINT-19- 00844; GeneralitatValenciana, Grant/Award Number: GVA-COVID19/2021/036 and SEJI-2020- 011, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Virus detection by CRISPR-Cas9-mediated strand displacement in a lateral flow assay

  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Ruiz, Raúl
  • Martínez-Aviñó, Adrià
  • Ballesteros-Garrido, Rafael
  • Navarro, David
  • Campins-Falcó, Pilar
  • Rodrigo, Guillermo
In public health emergencies or in resource-constrained settings, laboratory-based diagnostic methods, such as RT-qPCR, need to be complemented with accurate, rapid, and accessible approaches to increase testing capacity, as this will translate into better outcomes in disease prevention and management. Here, we develop an original nucleic acid detection platform by leveraging the CRISPR-Cas9 and lateral flow immunochromatography technologies. In combination with an isothermal amplification that runs with a biotinylated primer, the system exploits the interaction between the CRISPR-Cas9 R-loop formed upon targeting a specific nucleic acid and a fluorescein-labelled probe to generate a visual readout on a lateral flow device. Our method enables rapid, sensitive detection of nucleic acids, achieving a limit of 1-10 copies/μL in 1 h at low temperature. We validated the efficacy of the method using clinical samples of patients infected with SARS-CoV-2. Compared to other assays, it operates with more accessible molecular elements and showcases a robust signal-to-noise ratio. Moreover, multiplexed detection was demonstrated using primers labeled with biotin and digoxigenin, achieving simultaneous identification of target genes on lateral flow devices with two test lines. We successfully detected SARS-CoV-2 and Influenza A (H1N1) in spiked samples, highlighting the potential of the method for multiplexed diagnostics of respiratory viruses. All in all, this represents a versatile and manageable platform for point-of-care testing, thereby supporting better patient outcomes and enhanced pandemic preparedness., Work supported by CRUE and Banco Santander (Fondo Supera Covid-19), CSIC PTI+ Global Health (NextGenerationEU Fund, regulation 2020/2094), Spanish Ministry of Science and Innovation (PDC2022-133941-I00 and PRE2019-088531), and Regional Government of Valencia (SEJI/2020/011 and GVA-COVID19/2021/036)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Virus detection by CRISPR-Cas9-mediated strand displacement in a lateral flow assay

  • Montagud-Martínez, Roser
  • Márquez-Costa, Rosa
  • Ruiz, Raúl
  • Martínez-Aviñó, Adrià
  • Ballesteros-Garrido, Rafael
  • Peris Navarro, David
  • Campins-Falcó, Pilar
  • Rodrigo, Guillermo
In public health emergencies or in resource-constrained settings, laboratory-based diagnostic methods, such as RT-qPCR, need to be complemented with accurate, rapid, and accessible approaches to increase testing capacity, as this will translate into better outcomes in disease prevention and management. Here, we develop an original nucleic acid detection platform by leveraging CRISPR-Cas9 and lateral flow immunochromatography technologies. In combination with an isothermal amplification that runs with a biotinylated primer, the system exploits the interaction between the CRISPR-Cas9 R-loop formed upon targeting a specific nucleic acid and a fluorescein-labeled probe to generate a visual readout on a lateral flow device. Our method enables rapid, sensitive detection of nucleic acids, achieving a limit of 1-10 copies/μL in 1 h at a low temperature. We validated the efficacy of the method by using clinical samples of patients infected with SARS-CoV-2. Compared with other assays, it operates with more accessible molecular elements and showcases a robust signal-to-noise ratio. Moreover, multiplexed detection was demonstrated using primers labeled with biotin and digoxigenin, achieving the simultaneous identification of target genes on lateral flow devices with two test lines. We successfully detected SARS-CoV-2 and Influenza A (H1N1) in spiked samples, highlighting the potential of the method for multiplexed diagnostics of respiratory viruses. All in all, this represents a versatile and manageable platform for point-of-care testing, thereby supporting better patient outcomes and enhanced pandemic preparedness., This work was supported by CRUE and Banco Santander(Fondo Supera Covid-19), CSIC PTI+ Global Health(NextGenerationEU/PRTR), Spanish Ministry of Scienceand Innovation and AEI/10.13039/501100011033(PDC2022-133941-I00 and PRE2019-088531, cofinanced byNextGenerationEU/PRTR), and Regional Government ofValencia (SEJI/2020/011, GVA-COVID19/2021/036, CI-PROM/2022/21, and CIPROM/2023/46)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Engineering of CRISPR-Cas9-Based Systems for Diagnostics and Biocomputing

  • Márquez-Costa, Rosa
Grado internacional de Doctora en Biotecnología., [EN] CRISPR-Cas systems are based on an adaptive immune system mechanism found in bacteria and archaea. They function using RNA-guided endonucleases (Cas proteins), to target and recognize specific nucleic acid sequences. CRISPR-Cas systems are revolutionary in the field of genetic engineering, enabling specific genome editing, gene regulation assays and, developed in recent years, diagnostic applications. Nucleic acid detection methods are the gold-standard diagnostic technique in the clinic due to their high sensitivity and specificity. However, going forward, we must develop versatile virus detection methods that enable fast and reliable diagnostics and that can overcome the limitations of the current techniques and can be easily used outside the laboratory for point-of-care (POC) applications. CRISPR-Cas systems have been repurposed as nucleic acid diagnostic tools made possible by the ability of some Cas proteins to perform non-specific collateral cleavage upon target recognition. We aim to expand the CRISPR-Cas diagnostic toolkit by developing a novel nucleic acid detection strategy based on CRISPR-Cas9, whose mode of action relies on strand displacement rather than on collateral catalysis. We show that SARS-CoV-2 DNA amplicons generated from patient samples can be detected with CRISPR-Cas9. We also demonstrate the ability to perform simultaneous detection of different DNA amplicons with the same nuclease, either to identify different SARS-CoV-2 regions or different respiratory viruses. To advance toward POC applications, we coupled the isothermal preamplification step with biotinylated oligos to produce labelled amplicons. When combined with CRISPR-Cas9 targeting and FAM-labelled probes, this allows for colorimetric visualization of detection using lateral flow assays (LFA) on commercially available strips. The colorimetric readout enables interpretation of the results with the naked eye, surpassing the need for a fluorimeter. We successfully detected SARS-CoV-2 from patient samples in the LFA setup, and when combined with multiplexed RT-RPA, the detection of two distinct regions of the virus was achieved in a single test. Furthermore, the absence of collateral activity in our methodology allows for the processing of additional downstream sequences. Therefore, we also aim to explore the signal integration capability of our CRISPR-Cas9-based detection method. We demonstrate that engineered DNA logic circuits can process different SARS-CoV-2 signals detected by the CRISPR complexes. We also aimed to enhance our CRISPR-Cas9 system to sense both proteins and nucleic acids. We aimed to engineer a conditional guide RNA that responds to the presence of the SARS-CoV-2 spike protein. To achieve this, we inserted an aptamer sequence within the guide RNA to block Cas9 activity in the absence of the protein. Upon the presence of the spike protein, aptamer-protein interaction makes the blocking motif undergo a conformational change, releasing the guide RNA and activating Cas9. While we successfully achieved the blocking scenario using the regulatory sequences, further work is needed to identify a sequence that can induce the specific conformational change required to restore Cas9 activity upon spike protein presence. Collectively, this CRISPR-Cas9 diagnostic platform allows a multiplexed detection in a single tube, complementing the existing CRISPR-based methods, and offering an extensible system for applications in point-of-care diagnostics and biocomputing., [ES] Los sistemas CRISPR-Cas se basan en un mecanismo del sistema inmune adaptativo que se encuentra en bacterias y arqueas. Funcionan utilizando endonucleasas guiadas por ARN (proteínas Cas) para localizar y reconocer secuencias específicas de ácidos nucleicos. Los sistemas CRISPR-Cas son revolucionarios en el campo de la ingeniería genética, permitiendo la edición específica del genoma, ensayos de regulación genética y, desarrolladas en los últimos años, aplicaciones de diagnóstico. Los métodos de detección de ácidos nucleicos son la técnica de diagnóstico de referencia en la clínica debido a su alta sensibilidad y especificidad. Sin embargo, de cara al futuro, debemos desarrollar métodos versátiles de detección de virus que permitan diagnósticos rápidos y fiables, que superen las limitaciones de las técnicas actuales y puedan usarse fácilmente fuera del laboratorio para aplicaciones en puntos de atención (POC). Los sistemas CRISPR-Cas se han reconvertido en herramientas de diagnóstico de ácidos nucleicos gracias a la capacidad de algunas proteínas Cas de realizar cortes colaterales no específicos al reconocer su diana. Nuestro objetivo es ampliar el conjunto de herramientas de diagnóstico CRISPR-Cas mediante el desarrollo de una nueva estrategia de detección de ácidos nucleicos basada en CRISPR-Cas9, cuyo modo de acción se basa en el desplazamiento de hebra en lugar de en la catálisis colateral. Demostramos que los amplicones de ADN del SARS-CoV-2 generados a partir de muestras de pacientes pueden detectarse con CRISPR-Cas9. También demostramos la capacidad de realizar la detección simultánea de diferentes amplicones de ADN con la misma nucleasa, ya sea para identificar diferentes regiones de SARS-CoV-2 o diferentes virus respiratorios. Para avanzar hacia aplicaciones POC, acoplamos el paso de preamplificación isotérmica con oligos biotinilados para producir amplicones marcados. Cuando se combina con CRISPR-Cas9 y sondas marcadas con FAM, esto permite la visualización colorimétrica de la detección mediante ensayos de flujo lateral (LFA) en tiras disponibles en el mercado. La lectura colorimétrica permite la interpretación de los resultados a simple vista, superando la necesidad de un fluorímetro. Detectamos con éxito SARS-CoV-2 a partir de muestras de pacientes en la configuración LFA, y cuando se combinó con RT-RPA multiplexado, se logró la detección de dos regiones distintas del virus en una sola prueba. Además, la ausencia de actividad colateral en nuestra metodología permite el procesamiento de secuencias posteriores adicionales. Por lo tanto, también pretendemos explorar la capacidad de integración de señales de nuestro método de detección basado en CRISPR-Cas9. Demostramos que diseños de circuitos lógicos de ADN pueden procesar diferentes señales de SARS-CoV-2 detectadas por los complejos CRISPR. También nos propusimos mejorar nuestro sistema CRISPR-Cas9 para detectar tanto proteínas como ácidos nucleicos. Nos propusimos diseñar un ARN guía condicional que respondiera a la presencia de la proteína spike del SARS-CoV-2. Para ello, insertamos un aptámero en el ARN guía para bloquear la actividad de Cas9 en ausencia de la proteína. En presencia de la proteína spike, la interacción aptámero-proteína hace que el motivo de bloqueo sufra un cambio conformacional, liberando el ARN guía y activando Cas9. Aunque logramos con éxito el escenario de bloqueo utilizando las secuencias reguladoras, es necesario seguir trabajando para identificar una secuencia que pueda inducir el cambio conformacional específico necesario para restaurar la actividad de Cas9 en presencia de la proteína spike. En conjunto, esta plataforma de diagnóstico CRISPR-Cas9 permite una detección multiplexada en un solo tubo, complementando los métodos existentes basados en CRISPR, y ofreciendo un sistema extensible para aplicaciones en diagnóstico en el punto de atención y biocomputación., [CA] Els sistemes CRISPR-Cas es basen en un mecanisme del sistema immunitari adaptatiu que es troba en bacteris i arqueus. Funcionen utilitzant endonucleases guiades per ARN (proteïnes Cas) per tal de dirigir-se i reconéixer seqüències específiques d'àcids nucleics. Els sistemes CRISPR-Cas siguen revolucionaris en el camp de l'enginyeria genètica, permetent l'edició específica del genoma, assajos de regulació gènica i, desenvolupades en els darrers anys, aplicacions de diagnòstic. Els mètodes de detecció d'àcids nucleics són la tècnica de diagnòstic de referència a la clínica degut a la seua alta sensibilitat i especificitat. No obstant, de cara al futur, hem de desenvolupar mètodes versàtils de detecció de virus que permeten diagnòstics ràpids i fiables, que superen les limitacions de les tècniques actuals i puguen utilitzar-se fàcilment fora del laboratori per a aplicacions en punts d'atenció (POC). Els sistemes CRISPR-Cas han estat reorientats com a eines de diagnòstic d'àcids nucleics, fet possible per la capacitat d'algunes proteïnes Cas de realitzar un tall col·lateral no específic en reconèixer un objectiu. El nostre objectiu és ampliar el conjunt d'eines de diagnòstic CRISPR-Cas desenvolupant una nova estratègia de detecció d'àcids nucleics basada en CRISPR-Cas9, el mode d'acció del qual es basa en el desplaçament de cadena en lloc de la catàlisi col·lateral. Mostrem que es poden detectar amplicons de DNA de SARS-CoV-2 generats a partir de mostres de pacients amb CRISPR-Cas9. També demostrem la capacitat de realitzar la detecció simultània de diferents amplicons de DNA amb la mateixa nucleasa, ja siga per identificar diferents regions de SARS-CoV-2 o diferents virus respiratoris. Per avançar cap a aplicacions de punt d'atenció (POC), vam combinar el pas de preamplificació isotèrmica amb oligos biotinilats per produir amplicons etiquetats. Quan es combinen amb l'orientació CRISPR-Cas9 i sondes etiquetades amb FAM, això permet la visualització colorimètrica de la detecció mitjançant assajos de flux lateral (LFA) en tires comercials disponibles. La lectura colorimètrica permet la interpretació dels resultats a simple vista, superant la necessitat d'un fluorímetre. Vam detectar amb èxit el SARS-CoV-2 a partir de mostres de pacients en el sistema LFA, i quan es va combinar amb RT-RPA multiplexada, es va aconseguir la detecció de dues regions diferents del virus en una sola prova. A més, l'absència d'activitat col·lateral en la nostra metodologia permet el processament de seqüències addicionals. Per tant, també ens proposem explorar la capacitat d'integració de senyals del nostre mètode de detecció basat en CRISPR-Cas9. Demostrem que els circuits lògics d'ADN dissenyats poden processar diferents senyals de SARS-CoV-2 detectats pels complexos CRISPR. També vam intentar millorar el nostre sistema CRISPR-Cas9 per detectar tant proteïnes com àcids nucleics. Ens vam proposar dissenyar un ARN guia condicional que respon a la presència de la proteïna spike del SARS-CoV-2. Per aconseguir-ho, vam inserir una seqüència d'aptàmer dins de l'ARN guia per bloquejar l'activitat de Cas9 en absència de la proteïna. En presència de la proteïna spike, la interacció aptàmer-proteïna fa que el motiu de bloqueig experimente un canvi conformacional, alliberant l'ARN guia i activant Cas9. Tot i que vam aconseguir amb èxit el bloqueig utilitzant les seqüències reguladores, es necessita més treball per identificar una seqüència que puga induir el canvi conformacional específic necessari per restaurar l'activitat de Cas9 en presència de la proteïna spike. Col·lectivament, aquesta plataforma de diagnòstic CRISPR-Cas9 permet una detecció multiplexada en un sol tub, complementant els mètodes existents basats en CRISPR i oferint un sistema extensible per a aplicacions en diagnòstics de punt d'atenció i biocomputació., This work was supported by a predoctoral fellowship from the Spanish Ministry of Science and Innovation (PRE2019-088531)., Peer reviewed